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The World Health Organization (WHO) Collaborating Centres for Reference and Research on Inﬂuenza
(WHO CCs) tested 13,312 viruses collected by WHO recognized National Inﬂuenza Centres between May
2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors
(NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the
WHO CCs were from three WHO regions: Western Paciﬁc, the Americas and Europe. Approximately 0.5%
(n ¼ 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n ¼ 56)
against at least one of the four NAIs.
Of the twelve viruses with HRI, six were A(H1N1)pdm09 viruses, three were A(H3N2) viruses and
three were B/Yamagata-lineage viruses. The overall frequency of viruses with RI or HRI by the NAIs was
lower than that observed in 2013e14 (1.9%), but similar to the 2012e13 period (0.6%). Based on the
current analysis, the NAIs remain an appropriate choice for the treatment and prophylaxis of inﬂuenza
virus infections.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).for Reference and Research on Inﬂuenza, VIDRL, Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St,
.C. Hurt).
r B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The ﬁrst class of inﬂuenza antiviral drugs to be approved, the
adamantanes (namely amantadine and rimantadine), continue to
be ineffective for the treatment of inﬂuenza due to resistance
conferred by a S31N amino acid substitution in the M2 protein of
virtually all currently circulating A(H1N1)pdm09 and A(H3N2) vi-
ruses. The neuraminidase inhibitor (NAI) class of inﬂuenza antivi-
rals ﬁrst came to market in 1999 and now encompasses four
compounds e oseltamivir (Tamiﬂu®), zanamivir (Relenza®), per-
amivir (Rapivab®) and laninamivir (Inavir®) - that differ in their
chemical structure, bioavailability and mode of administration. In
the majority of countries, only oseltamivir and inhaled zanamivir
are approved, with oseltamivir being the most widely used.
Together with oseltamivir and zanamivir, peramivir and lanina-
mivir are approved and used in Japan, and peramivir is also
approved in China, the Republic of Korea and the USA. The use of
inﬂuenza antivirals differs around the world; countries such as
Japan and the USA use the greatest volumes and regularly treat
inﬂuenza virus infected patients presenting at general practitioners
or hospital outpatient clinics, while other countries primarily use
the drugs to treat severely ill hospitalised patients. Aside from the
treatment of seasonal inﬂuenza, several countries around theworld
have stockpiled large volumes of inﬂuenza antivirals for use in a
pandemic situation. Other inﬂuenza antivirals that target other
viral proteins or host factors, such as nitazoxanide, favipiravir and
ﬂudase, are currently in late-phase clinical trials but as yet have not
been approved for use in patients with uncomplicated inﬂuenza
infections. As such there remains a strong reliance on the NAIs,
speciﬁcally oseltamivir, for the treatment of severely ill patients.
Surveillance for viruses with reduced NAI susceptibility is
important to inform pandemic preparedness strategies and ensure
that treatment and clinical management guidelines remain
appropriate. Here we describe the third global update of NAI sus-
ceptibility for viruses collected through the World Health Organi-
zation (WHO) Global Inﬂuenza Surveillance and Response System
(GISRS) for the period May 2014 to May 2015 (subsequently
referred to as 2014e15).
Emergence of viruses with reduced NAI susceptibility is not
unprecedented and has been observed over the last decade both on
a local and global scale. For example, in late 2007 former seasonal
A(H1N1) viruses acquired the neuraminidase (NA) H275Y amino
acid substitution which conferred oseltamivir resistance, impacted
clinical effectiveness (Kawai et al., 2009a, 2009b), and spread
globally in less than 12 months (Dharan et al., 2009; Hurt et al.,
2009; Lackenby et al., 2008; Meijer et al., 2009). More recently,
clusters of A(H1N1)pdm09 viruses containing NA H275Y substitu-
tion have been detected at a local level (Hurt et al., 2011; Takashita
et al., 2015a). Two of these clusters, in Hokkaido, Japan and Penn-
sylvania, USA were described in our last annual report of NAI sus-
ceptibility for the 2013e14 period (Takashita et al., 2015b). These
events show that some former seasonal A(H1N1) and A(H1N1)
pdm09 viruses containing the NA H275Y amino acid substitution
are able to replicate and transmit as efﬁciently as normal wild-type
viruses. The presence of other permissive amino acid substitutions
are thought to restore the usual deteriorating effect of the NA
H275Y substitution on viral ﬁtness (Butler et al., 2014; Abed et al.,
2015).
2. Overall analysis of phenotypic antiviral susceptibility data
from WHO CCs
As part of the WHO GISRS network, over 140 WHO National
Inﬂuenza Centres (NICs) (http://www.who.int/inﬂuenza/gisrs_
laboratory/national_inﬂuenza_centres/en/) receive and conductpreliminary analyses on inﬂuenza viruses collected within their
countries. A representative number of these viruses are then for-
warded to at least one of ﬁve WHO Collaborating Centres (WHO
CCs) (Atlanta, USA; Beijing, China; London, United Kingdom; Mel-
bourne, Australia; and Tokyo, Japan) (http://www.who.int/
inﬂuenza/gisrs_laboratory/collaborating_centres/en/) for more
detailed virus characterisation.
Where available, patient-speciﬁc data including age, gender,
geographic location, healthcare setting, inﬂuenza antiviral treat-
ment history and immune status (immunocompromised or
immunocompetent) are included in the analysis. Availability of
antiviral treatment data was limited for many of the samples tested
but for all viruses showing reduced inhibition by any NAI this in-
formation was sought retrospectively. Because the majority of vi-
ruses analysed were collected from patients at the time of disease
onset (i.e. prior to any commencement of antivirals), the data
provides insights on the NAI susceptibility of circulating viruses as
opposed to the risk of emergence of viruses with reduced suscep-
tibility in NAI treated patients.
Viruses were typically passaged once or twice in MDCK or
MDCK-SIAT1 cells by WHO CCs before being analysed by pheno-
typic NA inhibition assay to assess NAI susceptibility. The NAI assays
utilised the ﬂuorescence-based substrate 2’-(4-
Methylumbelliferyl)-a-D-N-acetylneuraminic acid, sodium salt
hydrate (MUNANA) as previously described (Potier et al., 1979), but
with minor modiﬁcations in each laboratory (Takashita et al.,
2015b). All ﬁve WHO CCs tested for susceptibility to oseltamivir
and zanamivir, while the Atlanta, Melbourne and Tokyo WHO CCs
also tested isolates for susceptibility to peramivir and laninamivir.
As in the two previous global analysis reports (Meijer et al.,
2014; Takashita et al., 2015b), to facilitate pooled analysis of the
IC50 phenotypic data (the concentration of drug required to inhibit
standardised amount of NA activity by 50%) generated in the ﬁve
WHO CCs, data were converted into relative fold-change values
based on WHO CC, assay technique and subtype/lineage of virus.
Box-and-whisker plots based on log transformed IC50 fold-change
data were generated using Tukey’s method. Using the stand-
ardised deﬁnitions for reporting NAI susceptibility data (WHO,
2012), viruses were classiﬁed as showing either normal inhibition
(NI), reduced inhibition (RI) or highly reduced inhibition (HRI)
based on their fold differences compared to the median of viruses
from the same type/subtype/lineage showing NI. Brieﬂy, inﬂuenza
A viruses are classiﬁed as RI if they have a 10- to 100-fold higher
IC50 or HRI if they have a >100-fold higher IC50 than the relevant
median. For inﬂuenza B viruses RI viruses have a 5- to 50-fold
higher IC50 while HRI viruses have a >50-fold higher IC50 than
the relevant median.
Data presented here includes analysis of viruses collected be-
tween week 21/2014 (May 19th, 2014) and week 20/2015 (May
17th, 2015). During this period, the number of viruses collected and
submitted to WHO CCs peaked during the Southern and Northern
Hemisphere winter seasons in weeks 27 (2014) and 2 (2015)
respectively (Fig. 1A). Over the 2014e2015 period, a total of 13,312
viruses were tested for NAI susceptibility by the WHO CCs, a 25%
increase compared to the number tested in the equivalent
2013e2014 period (Takashita et al., 2015b). The majority of viruses
were A(H3N2) (6876; 51.6%) and B/Yamagata-lineage (3594; 27.0%),
with lower proportions of A(H1N1)pdm09 (2115; 15.9%) and B/
Victoria-lineage viruses (727; 5.5%) (Fig. 1B). In comparison, the
predominant inﬂuenza virus type/subtype collected and tested in
the 2013e2014 period was A(H1N1)pdm09 (48%). As has been
observed in previous studies, the majority of viruses tested came
from the Western Paciﬁc WHO region (56%), followed by the
Americas (29%) and Europe (9%). Only small proportions of viruses
were received and tested from the WHO regions of Eastern
Fig. 1. Inﬂuenza viruses collected and tested for phenotypic neuraminidase inhibitor (NAI) susceptibility during 2014e2015. A) Week of specimen collection and virus type/subtype/
lineage; for specimens tested, peaks in specimen collection during the Southern Hemisphere winter and during the Northern Hemisphere winter were observed. B) Number of
viruses tested for phenotypic susceptibility to the four NAIs by World Health Organization region. B/Yamagata-lineage haemagglutinin:B/Victoria-lineage neuraminidase reas-
sortants are shown separately.
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Of the 13,312 viruses tested, 68 (0.5%) showed RI or HRI by one
or more of the NAIs, a lower proportion than observed during the
2013e14 period (204/10,641; 1.9%) (Figs. 2 and 3; Tables 1 and 2).
The NA genes from the 68 RI/HRI viruses were sequenced and 50
were found to contain amino acid substitutions compared to cor-
responding consensus sequences from wild-type viruses showing
NI (Tables 1 and 2). NA genes were sequenced using standard
procedures which differed slightly between laboratories. An
example protocol from the Melbourne WHO CC is described in
Deng et al. (2015) with speciﬁc NA segment primers from that
procedure listed in Supplementary Table 1. Unfortunately many of
the clinical specimens, from which the RI/HRI viruses with NA
substitutions were recovered, were unavailable for sequence
analysis (n ¼ 30), but of those that were, 18 contained the same NAamino acid substitution present in the isolate, while two did not,
suggesting that those substitutions arose during cell culture
(Tables 1 and 2).
3. A(H1N1)pdm09 viruses showing RI or HRI
Of 2115 A(H1N1)pdm09 viruses tested, 11 (0.5%) showed RI or
HRI by one or more of the NAIs (Fig 2; Table 1). Of these, six viruses
were NA H275Y variants, showing HRI by oseltamivir (559- to 856-
fold greater than the median) and RI/HRI by peramivir (94- to 212-
fold greater), while retaining NI by zanamivir and laninamivir
(Fig. 2; Table 1). The NA H275Y variant viruses were collected from
patients within Australia (n¼ 3), Hawaii, Ukraine and France. Three
of the patients were treated with oseltamivir prior to sample
collection, two of whom were immunocompromised (Table 1).
Fig. 2. Column-scatter plots of log-transformed 50% inhibitory concentration (IC50) fold-change values. Data are presented by virus subtype or lineage (A, A(H1N1)pdm09; B,
A(H3N2); C, B/Victoria-lineage; D, B/Yamagata-lineage) and neuraminidase inhibitor (labelled on the X-axis: oseltamivir, zanamivir, peramivir, laninamivir). Panel C also contains B/
Yamagata-lineage haemagglutinin:B/Victoria-lineage neuraminidase reassortants, of which the one with amino acid substitution is indicated with an asterisk (*) in the peramivir
column. The boxes indicate the 25e75 percentile and the whiskers stretch to the lowest and highest value within 1.5 times the interquartile region value from both the 25 and 75
percentile values respectively (Tukey’s deﬁnition). The Y-axes have been split into 3 compartments according to the World Health Organization Antiviral Working Group rec-
ommended thresholds for normal inhibition (NI) (A viruses <10-fold; B viruses <5-fold), reduced inhibition (RI) (A viruses 10- to 100-fold; B viruses 5- to 50-fold), and highly
reduced inhibition (HRI) (A viruses >100-fold; B viruses >50-fold). For RI and HRI viruses that have been sequenced the determined NA amino acid substitutions are shown; amino
acid position numbering is A subtype and B type speciﬁc. All viruses were tested for susceptibility to oseltamivir and zanamivir but not all, including some variants, were tested
against peramivir and laninamivir.
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Fig. 3. A) Proportions of viruses showing RI or HRI by neuraminidase inhibitors over
the 2012e2015 period. B) Number of viruses tested in NA inhibition assays. Data
compiled from the global studies reporting on viruses isolated during 2012e13 (Meijer
et al., 2014), 2013e14 (Takashita et al., 2015b) and 2014e15 (this study).
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ants were detected (3.3% of the number tested) from predomi-
nantly Japan, China and USA, there was a substantial reduction in
the detection of these variants in the 2014e2015 period, although
this may be due to the lower number of A(H1N1)pdm09 viruses
circulating.
A single A(H1N1)pdm09 virus with a NA I223R amino acid
substitution was isolated from a patient in Bolivia (Fig. 2, Table 1).
This virus showed RI by oseltamivir (58-fold greater IC50 than the
median) and zanamivir (10-fold greater) but retained NI by per-
amivir and laninamivir (Fig. 2, Table 1). Of the remaining four vi-
ruses with RI by one or more of the NAIs, one contained dual T157I/
D214G NA amino acid substitutions, while sequence analysis of the
other three A(H1N1)pdm09 viruses failed to identify any NA sub-
stitutions that were either novel or associated with RI by NAIs
(Fig. 2, Table 1).4. A(H3N2) viruses showing RI or HRI
Seventeen (0.2%) out of 6876 A(H3N2) viruses showed RI or HRI
by one or more of the NAIs. Seven of these contained NA Q136K
amino acid substitution that confers RI by zanamivir (Fig. 2,
Table 1). This substitution has typically been reported to arise
during cell culture propagation (Little et al., 2015) butunfortunately, for the seven isolates with this substitution, none of
the respective clinical specimens were available to determine if this
was the case. Three A(H3N2) viruses contained dual I222T/S331R
amino acid substitutions that resulted in RI by oseltamivir (Fig. 2,
Table 1). As single substitutions, neither I222T nor S331R alone
confers sufﬁcient IC50 rises to be classiﬁed as RI, but as a combi-
nation they synergistically raised oseltamivir IC50 by 12- to 31-fold
(Table 1).
Five viruses with RI/HRI due to various NA amino acid sub-
stitutions were isolated from patients undergoing NAI treatment
(Table 1). Two patients shed viruses containing NA E119V amino
acid substitution that conferred RI/HRI by oseltamivir (25- to 303-
fold) (Fig. 2), one received oseltamivir while the other (from Japan)
received oseltamivir and peramivir and was immunocompromised
(Table 1). Another immunocompromised patient from Japan, who
was infected with A(H3N2) inﬂuenza and treated with oseltamivir
and peramivir, shed viruses containing NA R292K amino acid
substitution which conferred a massive 27,416-fold increase in
oseltamivir IC50 as well as conferring HRI by peramivir (271-fold)
and RI by zanamivir (12-fold) (Fig. 2; Table 1).
A NA D151A amino acid substitution was detected in an isolate
that had RI by zanamivir (43-fold), but sequencing showed that the
substitution was not present in the clinical specimen, thereby
suggesting that it had arisen during cell culture, as has been re-
ported previously for this substitution (Okomo-Adhiambo et al.,
2010). Two other A(H3N2) viruses with less commonly identiﬁed
NA amino acid substitutions were also detected in 2014e15. The
ﬁrst was a virus from the USA that contained NA N142S amino acid
substitution that unusually conferred HRI or RI by all four NAIs (HRI
to oseltamivir and zanamivir and RI to peramivir and laninamivir),
while the second virus contained NA G320E amino acid substitu-
tion that caused RI by oseltamivir (17-fold) (Fig. 2; Table 1).
5. B/Victoria-lineage viruses showing RI or HRI
Five (0.7%) of the 727 B/Victoria-lineage viruses (which included
35 B/Yamagata-lineage HA:B/Victoria-lineage NA reassortants)
showed RI or HRI by one or more of the NAIs. Three viruses
exhibited RI by peramivir and had IC50 values that were 8- to 14-
fold higher than the median, and contained single NA amino acid
substitutions of T106P, G104R/G and G145E respectively (Fig. 2;
Table 2). A virus from Honduras with NA I221T amino acid substi-
tution showed RI by both oseltamivir (7-fold) and peramivir (14-
fold) and a virus from Bangladesh contained NA K152M amino
acid substitution that resulted in a 5-fold increase in oseltamivir
IC50 (Fig. 2; Table 2). Unfortunately, no information about antiviral
treatment or the immune status of the patients was available for
these ﬁve cases.
6. B/Yamagata-lineage viruses showing RI or HRI
Of the 3594 B/Yamagata-lineage viruses tested, 35 (1.0%) had RI
or HRI by one or more of the NAIs. Twelve of these viruses con-
tained NA D197N amino acid substitution that conferred 4- to 11-
fold increases in oseltamivir IC50, 2- to 11-fold increases in zana-
mivir IC50 and 5- to 29-fold increases in peramivir IC50 (Fig. 2;
Table 2). Three NA D197N variants were from Australia, three from
the USA, ﬁve from China and one from the Ukraine (Table 2).
Interestingly, the three viruses from Australia had identical HA and
NA sequences and two of these (B/South Australia/2/2015 and B/
South Australia/5/2015) were from a father and son who lived
together. While there was no epidemiological link to the third
Australian case, it is noteworthy that the specimen collection date
differed by only 7 days from that which yielded B/South Australia/
2/2015 virus. One of the NA D197N variants from China (B/Tianjin-
Table 1
Virus and patient characteristics of 28 inﬂuenza A viruses showing RI or HRI, tested by WHO CCs.a
Virus n IC50 fold-change compared to reference
median IC50 valuesb
NA-substitutionc Patient setting Antiviral treatment prior to specimen
collection
Oseltamivir Zanamivir Peramivir Laninamivir Virus
isolate
Clinical specimen
A(H1N1)
pdm09;
N ¼ 2115
6 559e856 0.9e1.9 94 e 212
(5)
1.5e2.6 (5) H275Y H275Y (4) Not available
(2)
GP/Outpatient (1)
Hospital (3) Unknown (2)
Yes, oseltamivir (2) Yes, antiviral
unknown (1) No (2) Unknown (1)
1 14 7.0 1.6 1.3 T157I,
D214G
No sequence available,
poor quality data
GP/Outpatient No
1 58 10 7.2 2.2 I223R I223R Unknown Unknown
2 10e14 2.2e8.4 3.7 (1) 3.6 (1) None Not available (1) Not
sequenced (1)
GP/Outpatient No (1) Unknown (1)
1 1.6 2.0 12 1.9 None Not sequenced Hospital No
A(H3N2);
N ¼ 6876
7 0.3e1.1 11e36 2.9e9.0
(2)
2.0e3.6 (2) Q136K Not available Hospital (5) Unknown (2) Unknown
3 12e31 2.9e7.2 1.6e2.4 2.5e3.6 I222T,
S331R
I222T, S331R GP/Outpatient No
2 25e303 1.5e2.3 1.5e2.1 1.1e2.2 E119V E119V Hospital (1) Unknown (1) Yes, oseltamivir (1), oseltamivir and
peramivir (1)
1 595 244 40 53 N142S N142S Unknown Unknown
1 2.9 43 9.9 6.9 D151A Substitution not present GP/Outpatient Yes, zanamivir
1 27 146 12 271 2.7 R292K R292K Hospital Yes, oseltamivir and peramivir
1 17 8.4 3.3 1.9 G320E Not available Unknown Unknown
1 7.9 11 nd nd None Not available GP/Outpatient Yes, oseltamivir
a Between brackets the number of viruses for which data was reported if less than the number reported in column ‘n’. RI ¼ reduced inhibition; HRI ¼ highly reduced
inhibition; nd ¼ not done; None ¼ no amino acid substitutions compared to viruses with NI phenotype.
b RI and HRI fold-change values are displayed underlined and in bold typeface.
c Amino acid position numbering is A subtype speciﬁc.
Table 2
Virus and patient characteristics of 40 inﬂuenza B viruses showing RI or HRI, tested by WHO CCs.a
Virus n IC50 fold-change compared to reference
median IC50 valuesb
NA-substitutionc Patient setting Antiviral treatment prior to
specimen collection
Oseltamivir Zanamivir Peramivir Laninamivir Virus isolate Clinical specimen
B/Victoria-
lineage;
N ¼ 727d
1 1.1 2.9 14 0.7 T106Pd Not available Unknown Unknown
1 4.2 0.8 7.8 0.7 G104R/G
mix
Not available Unknown Unknown
1 0.7 0.7 14 0.4 G145E Not available Unknown Unknown
1 5.4 0.6 1.9 1.1 K152M Not available Unknown Unknown
1 6.8 3.7 14 1.4 I221T Not available Unknown Unknown
B/Yamagata-
lineage;
N ¼ 3594
12 4.4e11 2.2e11 5.4 e 29
(6)
1.6e3.3 (6) D197N D197N (4) Not available (7)
Not sequenced (1)
GP/Outpatient (4)
Hospital (5) Unknown (2)
No (3) Unknown (8)
3 7.9e15 4.1e5.4 28e35 1.7e1.9 I221T I221T (1) Not available (2) GP/Outpatient (1)
Hospital (1) Unknown (1)
No (1) Unknown (2)
1 1.7 1.8 28 1.2 H101L/H
mix, D342S
Not available Unknown Unknown
1 2.0 1.0 145 0.8 T146I Substitution not present GP/Outpatient No
1 3.3 5.4 nd nd D197G Substitution not present GP/Outpatient Yes, oseltamivir
1 5.2 1.0 120 0.6 H273Y H273Y Unknown Unknown
1 8.1 55 nd nd A245T Not available Hospital Unknown
15 0.8e24 0.2e31 0.8 e 10
(14)
1.3e4.2
(14)
None Not available GP/Outpatient (7)
Hospital (1) Unknown (7)
No (1) Unknown (14)
a Between brackets the number of viruses for which data was reported if less than the number reported in column ‘n’. RI ¼ reduced inhibition; HRI ¼ highly reduced
inhibition; nd ¼ not done; None ¼ no amino acid substitutions compared to viruses with NI phenotype.
b RI and HRI fold-change values are displayed underlined and in bold typeface.
c Amino acid position numbering is B type speciﬁc.
d 35 of these viruses are B/Yamagata-lineage haemagglutinin (HA) e B/Victoria-lineage neuraminidase (NA) reassortants; because the NA deﬁnes the IC50 values these
viruses are listed in the B/Victoria-lineage category. One of these viruses had NA T106P.
A.C. Hurt et al. / Antiviral Research 132 (2016) 178e185 183Hedong/834/2015) was collected in the same time period as the
Australian viruses and the HA and NA sequences of these four
viruses clustered closely in the phylogenies (Supplementary
Fig. S1). Two Chinese NA D197N variants, collected in September
and October 2014 (B/Anhui-Baohe/1680/2014 and B/Shanghai-
Pudongxin/11568/2014), also had identical HA and NA sequences.
From phylogenetic analyses of these variants over the last ﬁve
years, we also identiﬁed an early 2014 cluster of six Japanese
viruses with NA D197N substitution that had identical HA and NA
sequences, further suggesting that these viruses can spread in thecommunity (Supplementary Fig. S1). For NA D197N variants where
the respective clinical specimens were available (n ¼ 4), all con-
tained the amino acid substitution and none of the patients had
been treated with an NAI. Three inﬂuenza B NA D197N variants (2
from the B/Yamagata-lineage and one from the B/Victoria-lineage)
were detected through phenotypic analysis in the equivalent
2013e2014 period, one of which was collected from a patient being
treated with zanamivir (Takashita et al., 2015b). Another B/
Yamagata-lineage virus from Spain carried NA D197G amino acid
substitution which conferred a 5-fold increase in oseltamivir IC50;
A.C. Hurt et al. / Antiviral Research 132 (2016) 178e185184unfortunately the clinical specimen yielding this virus isolate was
not available (Fig. 2; Table 2).
Three viruses with NA I221T amino acid substitution that
conferred RI by oseltamivir (8- to 15-fold), zanamivir (4- to 5-fold)
and peramivir (28- to 35-fold) were collected from patients in
Japan, Russia and China (Fig. 2; Table 2). Three other B/Yamagata-
lineage viruses, all with different NA amino acid substitutions
(T146I, H273Yand A245T), demonstrated HRI by either peramivir or
zanamivir (Fig. 2; Table 2), but sequence analysis of the relevant
clinical specimen revealed that the T146I substitution arose during
cell culture. A further 15 B/Yamagata-lineage viruses showed RI by
at least one of the NAIs but sequence analysis failed to reveal any
unique NA amino acid substitutions that were considered to be
associated with the change in IC50 (Fig. 2; Table 2).
7. Frequency of RI and HRI conferring NA amino acid
substitutions in sequence databases
The interrogation of public sequence databases to determine the
frequency of NA amino acid substitutions that confer RI or HRI by
the NAIs is a useful adjunct to the phenotypic data generated by the
WHO CCs. Analysis of the Global Initiative on Sharing All Inﬂuenza
Data (GISAID) (www.gisaid.org) and National Center for Biotech-
nology Information e Inﬂuenza Virus Resource (NCBI-IVR) (www.
ncbi.nlm.nih.gov/genomes/FLU/FLU.html) databases showed that
sequences from 7316 inﬂuenza viruses collected during the
2014e15 period had been deposited, of which 2440 (33%) were
from viruses that had not been tested by the WHO CCs in the
phenotypic analysis described above.
We analysed the NA sequences from the 2440 viruses (466
A(H1N1)pdm09; 1373 A(H3N2); 58 B/Victoria-lineage and 543 B/
Yamagata-lineage) to determine the number that contained amino
acid substitutions associated with reduced inhibition, as listed in
the summary table provided by the AVWG on the WHO website
(http://www.who.int/inﬂuenza/gisrs_laboratory/antiviral_
susceptibility/avwg2014_nai_substitution_table.pdf). Of the 466
A(H1N1)pdm09 virus NA sequences, four contained the H275Y
amino acid substitution (from France (n ¼ 2), Norway (n ¼ 1) and
Spain (n ¼ 1) that confers HRI by oseltamivir and peramivir, while
the E119V amino acid substitution, which confers RI/HRI by osel-
tamivir, was present in one of the 1373 A(H3N2) NA sequences.
Four NA sequences from the 543 B/Yamagata-lineage viruses con-
tained the same D197N amino acid substitution that was detected
in twelve variants tested in the phenotypic assay, and which
conferred RI by oseltamivir, zanamivir and peramivir; in addition
one NA sequence contained the H273Y amino acid substitution
which confers HRI by peramivir.
8. Concluding remarks
Based on our current analysis, >99% of inﬂuenza viruses tested
during 2014e15 were susceptible to all four NAIs, indicating that
these antivirals remain an appropriate choice for the treatment and
prophylaxis of inﬂuenza virus infections. Viruses with RI or HRI
occurred across multiple regions and were not detected at higher
frequencies in countries where NAI usage is greatest (i.e. Japan and
the USA) (Supplementary Table 2). This is the third global update on
inﬂuenza NAI susceptibility based on data generated by the WHO
CCs’ analyses of viruses received from NICs throughout the world.
The overall frequency of viruses with RI or HRI by the NAIs was
highest in 2013e14 (1.9%), compared to 2012e13 and the most
recent 2014e15 period where the frequencies were 0.6% and 0.5%
respectively (Fig. 3). The higher frequency of RI/HRI viruses in
2013e14 was due mainly to A(H1N1)pdm09 being the dominant
inﬂuenza A subtype with an associated increased detection ofA(H1N1)pdm09 viruses with NA H275Y amino acid substitution,
with clusters of cases being detected in Japan, the USA and China
(Takashita et al., 2015b). Of the different types/subtypes, B/
Yamagata-lineage viruses had the highest frequency of RI/HRI vi-
ruses in the 2014e15 period, of which variants with NA D197N
amino acid substitution were the most prevalent. Given the close
genetic similarity across the HA and NA of some NA D197N variants
in Australia and China it is possible that some low level community
transmission of these viruses had occurred, so close monitoring of
inﬂuenza B viruses for this substitution will be important in up-
coming inﬂuenza seasons.
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